Anesthesia Pharmacology Chapter 29 Diabetes Management Practice Questions

Lixisenatide (Adlyxin): classified as an type 2 antidiabetic drug acting as a glucagon-like peptide-1 (GLP-1) receptor agonist.
1. True
2. False
Lixisenatide (Adlyxin):
1. Synthetic exendin 4 (exenatide) analog
2. Half-life greater than 24 hours.
3. Both
4. Neither
Lixisenatide pharmacology: comparable pharmacological effects to exenatide.
1. True
2. False
Lixisenatide administration is associated with:
1. An absence of effect on lowering HbA_1c
2. Weight loss
3. Both
4. Neither
Immunologic effect(s) associated with lixisenatide administration:
1. Lixisenatide antibodies are observed in about 70% of cases.
2. In about 2.5% of cases high antibody titers are associated with reduced glycemic response.
3. Both
4. Neither
Lixisenatide pharmacokinetics:
1. Elimination half-life is about 3-4 hours
2. Substantial hepatic clearance
3. Both
4. Neither
Lixisenatide (Adlyxin) although effective as monotherapy is not considered a first-line drug.
1. True
2. False
Lixisenatide (Adlyxin): used to manage type II diabetes mellitus along with diet and exercise.
1. True
2. False
May occur with lixisenatide administration:
1. Hypersensitivity reactions including anaphylaxis and angioedema.
2. Pancreatitis
3. Both
4. Neither
Drugs other than lixisenatide are presently suggested to treat diabetes mellitus in pregnancy (ADA 2020).
1. True
2. False
Lixisenatide adverse reactions/reactions occurring with a frequency than 10%:
1. Immunological, antibody development which in some patients may be sufficient to decrease glycemic drug effects.
2. Gastrointestinal symptoms (usually within the first few weeks.
3. Both
4. Neither
Lixisenatide (Adlyxin) route/routes of administration:
1. Intravenous
2. Intramuscular
3. Subcutaneous
4. Aerosol